Business Description
Climb Bio Inc. is a clinical-stage biotechnology company based in Wellesley Hills, Massachusetts, dedicated to creating treatments for patients with immune-related diseases. Its primary drug candidate, budoprutug, is an antibody that targets B-cell driven conditions and is currently being tested in Phase 2 trials for membranous nephropathy and immune thrombocytopenia, as well as in a Phase 1b trial for lupus. The company is also advancing an early-stage antibody called CLYM116, aimed at treating IgA nephropathy and similar conditions. Formerly known as Eliem Therapeutics Inc., the company adopted its current name in October 2024.
